Abstract: The present invention relates to a recombinant microorganism imparted with increased ability to produce glutaric acid by further introducing a gene encoding a polypeptide having glutaric acid transporter activity into a microorganism having ability to produce glutaric acid, and to a method of preparing glutaric acid using the recombinant microorganism. According to the present invention, glutaric acid used for the preparation of various compounds such as polyamide, polyurethane, 1,5-pentanediol, and 5-hydroxyvaleric acid can be biosynthesized at high yield.
Type:
Grant
Filed:
December 13, 2021
Date of Patent:
April 23, 2024
Assignee:
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: A method for producing 2-keto-3-deoxygluconate (KDG) from 2-(acetylamino)-2-deoxy-D-gluconic acid (GlcNAc1A) by two enzymes; GlcNAc1A is converted to KDG by incubating GlcNAc1A with a deacetylase OngB at 25° C. for 4-12 h and then with a deaminase OngC at 25° C. for another 10-15 h; it constructs two engineered E. coli/pET22b-ongB (carrying the ongB gene) and E. coli/pET22b-ongC (carrying the ongC gene) strains to prepare recombinant proteins OngB and OngC, respectively; at the action of these two enzymes, OngB and OngC, GlcNAc1A is converted to KDG, which solves the bottleneck of GlcNAc1A utilization during the bioconversion of chitin; the KDG is an important metabolic intermediate to synthesize furan derivatives, herbicides, food additives and other industrially important chemical compounds, having wide industrial applications.
Abstract: Provided are a fusion protein comprising a Pab1 element and an eIF4G element and a preparation method therefor. The fusion protein can improve in-vitro translation efficiency. A constitutive or inducible promoter (for example, pKlPGK1) may also be inserted in front of eIF4G in the fusion protein for increasing in-vitro protein synthesis ability.
Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
Abstract: Provided is an application of trehalase in fermentative production. The trehalase has amino acid sequences shown in SEQ ID NO.6, SEQ ID NO.7, and SEQ ID NO.8. Provided are methods for producing and applying trehalase, particularly being applied in the production and fermentation of alcohol and an amino acid.
Abstract: Disclosed are a recombinant acid-resistant yeast having improved lactic-acid-producing ability and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast according to the present invention, not only lactic-acid fermentation can be performed with lactic-acid-producing ability similar to that of bacterial fermentation using a remarkably smaller amount of a neutralizing agent than in the case of conventional bacterial fermentation, but also the production of ethanol and glycerol which are byproducts can be reduced. Thus, fermentation costs can be greatly reduced and the cost of subsequent purification processes can be reduced.
Type:
Grant
Filed:
June 21, 2021
Date of Patent:
February 13, 2024
Assignee:
SK Innovation Co., Ltd.
Inventors:
Jae Yeon Park, Tae Young Lee, Ki Sung Lee
Abstract: Artificial lipoproteins bearing non-canonical post-translational modifications that are synthesized by leveraging substrate promiscuity of an acyltransferase. The non-canonical functionality of these lipoprotein results in a distinctive hysteretic assembly that is absent from the canonical lipoproteins and is used to prepare hybrid multiblock materials with precise and programmable patterns of amphiphilicity due to the unique assembly and function of the non-canonical post-translational modifications.
Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
Type:
Grant
Filed:
May 17, 2022
Date of Patent:
November 14, 2023
Assignee:
Mammoth Biosciences, Inc.
Inventors:
Benjamin Julius Rauch, Aaron DeLoughery, William Douglass Wright, David Paez-Espino, Clarissa Oriel Rhines, Lucas Benjamin Harrington, Wiputra Jaya Hartono
Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12x.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.
Type:
Grant
Filed:
September 20, 2021
Date of Patent:
October 17, 2023
Assignee:
Precision BioSciences, Inc.
Inventors:
James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
Abstract: Presented herein are polymerase enzymes for improved incorporation of nucleotide analogues, in particular nucleotides which are modified at the 3? sugar hydroxyl, as well as methods and kits using the same.
Abstract: The present disclosure relates to consortia of bacteria strains and composition comprising one or more bacterial strains disclosed herein. These consortia of isolated bacteria cultures and compositions comprising said cultures, having greater activity than would be observed for the individual bacteria cultures and compositions. A composition of the disclosure may advantageously be used for enhancing the availability of soil phosphorus and other macronutrients and/or micronutrients to plants, and thereby enhancing their growth and yield.
Type:
Grant
Filed:
June 6, 2022
Date of Patent:
October 3, 2023
Assignee:
Colorado State University Research Foundation
Abstract: The invention related to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific matter. The poly peptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.
Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.
Type:
Grant
Filed:
September 13, 2022
Date of Patent:
September 12, 2023
Assignee:
Precision BioSciences, Inc.
Inventors:
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Abstract: A method of producing 3-oxoadipic acid from an aliphatic compound easily utilizable by a microorganism, such as a saccharide, by utilization of a metabolic pathway of the microorganism is disclosed.
Abstract: The present disclosure relates to methods for producing recombinant proteins, as well as compositions used in and produced by such methods. Specifically, the present disclosure relates to methods for producing high secreted yields of recombinant proteins, and the compositions provided herein include expression constructs, recombinant vectors, and recombinant host cells that comprise polynucleotide sequences encoding proteins operably linked to recombinant secretion signals that comprise the leader peptide of the ?-mating factor (?MF) of Saccharomyces cerevisiae and a non-?MF signal peptide.
Type:
Grant
Filed:
March 15, 2022
Date of Patent:
August 15, 2023
Assignee:
BOLT THREADS, INC.
Inventors:
Joshua Kittleson, Thomas Stevens, Rena Hill, Carlos Gustavo Pesce, David N. Breslauer, Daniel M. Widmaier
Abstract: The present invention aims to provide a modified Cas9 protein with relaxed restriction on target sequence while maintaining binding ability to guide RNA, and use thereof. A protein containing the amino acid sequence of SEQ ID NO: 1 in which the 1335-position arginine is mutated into alanine (R1335A), isoleucine (R1335I), methionine (R1335M), threonine (R1335T) or valine (R1335V), the 1111-position leucine is mutated into arginine (L1111R), the 1135-position aspartic acid is mutated into valine (D1135V), the 1218-position glycine is mutated into arginine (G1218R), the 1219-position glutamic acid is mutated into phenylalanine (E1219F), the 1322-position alanine is mutated into arginine (A1322R), and the 1337-position threonine is mutated into arginine (T1337R), and the like.
Abstract: Disclosed is a mutant strain having the ability to produce polyhydroxybutyrate. The novel strain has a significantly high growth rate and an improved ability to produce PHB compared to existing PHB-producing cyanobacterial strains. Therefore, the novel strain is suitable for use in the production of PHB and the development of various products using PHB. In addition, the novel strain is useful as a photosynthetic strain for developing a PHB production process using industrial flue gas due to its ability to produce PHB from only CO2 without any additional organic carbon source. Also disclosed is a method for producing polyhydroxybutyrate using the mutant strain.
Type:
Grant
Filed:
December 29, 2021
Date of Patent:
July 18, 2023
Assignee:
Korea University Research and Business Foundation
Inventors:
Sang Jun Sim, Hyejin Roh, Jeong Seop Lee
Abstract: Disclosed is the production by fermentation of poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). In particular, there is provided engineered (prokaryotic or eukaryotic) cells for the direct synthesis of PLLA polymers and engineered eukaryotic cells for the direct synthesis of PDLA polymers starting from a carbon source, including residual biomasses of the different production chains.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
July 11, 2023
Assignees:
UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA, GALATEA BIOTECH S.R.L.
Inventors:
Danilo Porro, Paola Branduardi, Stefano Bertacchi, Nadia Maria Berterame
Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
Type:
Grant
Filed:
January 21, 2021
Date of Patent:
July 4, 2023
Assignee:
CARGILL, INCORPORATED
Inventors:
Catherine Asleson Dundon, Pirkko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez